Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nscls: RTOG 94-10

Reviewer: Ryan Smith, MD
OncoLink
Ultima Vez Modificado: 1 de junio del 2003

Share article


English

Presenter: W.J. Curran
Presenter's Affiliation: RTOG
Type of Session: Scientific

Background

  • There has been a demonstrated survival benefit of chemoradiation over radiation alone in stage III non-small cell lung cancer (NSCLC)
  • This survival benefit has been demonstrated in several studies using sequential chemotherapy followed by radiation therapy.
  • The EORTC and CEBI showed an advantage of concurrent chemotherapy with radiation therapy.
  • This study was performed to detemine which approach is best

Materials and Methods

  • 610 patients were accrued over 4 years, with 595 evaluable
  • All had stage IIIA/IIIB or medically inoperable stage II disease, with a KPS >= 70 and weight loss <= 5%
  • Patients were randomized between 3 arms: Arm 1: SEQ-vinblastine 5 mg/m2/wk x 5 + cisplatin 100 mg/m2 days 1, 29 with radiation to 60 Gy (2 Gy per day) beginning on day 50 Arm 2: CON-vinblastine 5 mg/m2/wk x 5 + cisplatin 100 mg/m2 days 1, 29 with radiation to 60 Gy (2 Gy per day) beginning on day 1 Arm 3: BID-oral etoposide 50 mg BID x 10 weeks + cisplatin 50 mg/m2 days 1, 8, 15, 29, 36 with radiation to 69.6 Gy (1.2 Gy BID) beginning on day 1
  • Median follow-up time was 6 years, with minimum follow up of 4 years (therefore all results reported are actual-not actuarial)

Results

  • 75% of patients had KPS of 90-100 and just over 50% were stage IIIB
  • Median survival time was 14.6 mo, 17.0 mo, and 15.2 mo for Arms 1, 2, and 3, respectively
  • 4 year overall survival was 12%, 21%, and 17% for Arms 1, 2, and 3, respectively
  • This corresponded to a survival benefit, with Arm 2 compared to arm 1 (p=.046)
  • Acute toxicity was much higher in arms 2 and 3, most notably for grade 3-4 esophagitis (4% (Arm 1), 25% (arm 2), and 47% (arm 3))
  • There was no difference in acute pneumonitis rates (7%, 4%, 3%)
  • There was a low level of late esophageal toxicity in all groups (1%, 2%, 3%)
  • There was no difference in late pneumonitis between the groups, though this rate was higher than expected (13%, 11%, 13%)

Author's Conclusions

  • Concurrent chemoradiation had a significantly better survival when compared to sequential chemoradiation treatment
  • This concurrent treatment did confer a greater acute toxicity, but this did not result in any increased late toxicity
  • Arm 3 (BID radiation) had a much higher acute toxicity rate than the other arms, but without any additional survival benefit
  • Concurrent chemoradiation should now be considered the standard of care in stage III and inoperable NSCLC

Clinical/Scientific Implications

    Locally advanced NSCLC remains a challenging disease to treat, with the majority of patient still failing and succumbing to their disease. Starting with the Dillman trial, published over a decade ago, it has been shown that chemoradiation has a benefit over radiation alone. This study now defines the use of concurrent chemoradiation in this group of patients. This study shows an overall survival benefit with concurrent chemoradiation over radiation alone. However, patient selection will remain key, as this study enrolled only those patients with an excellent performance status and virtually no weight loss. This practice should continue to be employed, especially given the high rate of esophageal (and hematopoetic) toxicity as well as the surprisingly higher rate of late lung toxicity. However, this study, paired the Furuse study (which showed a 17% survival vs a 10% survival in terms of concurrent and sequential chemoradiation, p=.04) proves that concurrent chemoradiation should be the standard of care in good performance status patients with inoperable NSCLC.

Oncolink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.

English
News
Stage III/IV Melanoma Patients at Risk for New Primaries

Dec 10, 2013 - Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas, although the incidence rates are lower than those observed in studies of dabrafenib and vemurafenib, according to research published online Dec. 2 in the Journal of Clinical Oncology.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información